SEARCH

SEARCH BY CITATION

References

  • 1
    Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997; 4 (Suppl. 2): S1522.
  • 2
    Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol 2001; 16: 3746.
  • 3
    Koman LA, Mooney JF, Smith BP, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14: 299303.
  • 4
    Koman LA, Mooney JF, Patterson Smith B, Walker F, Leon JM, the BOTOX Study Group. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 2000; 20: 10815.
  • 5
    Sutherland DH, Kaufman KR, Wyatt M, Chambers HG, Mubarak SJ. Double blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999; 10: 19.
  • 6
    Ubhi T, Bhakta BB, Ivew HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000; 83: 48187.
  • 7
    Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 38696.
  • 8
    Zelnick N, Giladi N, Goikhman I, Keren G, Moris R, Honigman S. The role of botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy – a pilot study. Isr J Med Sci 1997; 33: 12933.
  • 9
    Fazzi E, Maraucci I, Torrielli S, Motta F, Lanzi G. Factors predicting the efficacy of botulinum toxin-A treatment of the lower limb in children with cerebral palsy. J Child Neurol 2005; 20: 6616.
  • 10
    Fattal-Valevski A, Giladi N, Domanievitz D, et al. Parameters for predicting favorable response to botulinum toxin in children with cerebral palsy. J Child Neurol 2002; 17: 2727.
  • 11
    Linder M, Schindler G, Michaelis U, et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol 2001; 8 (Suppl. 5): 1206.
  • 12
    Boyd RN, Graham JEA, Nattrass GR, Graham HK. Medium term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 1999; 6 (Suppl. 4): S3745.
  • 13
    Hägglund G, Andersson S, Düppe H, Lauge Pedertsen H, Nordmark E, Westbom L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B 2005; 14: 26973.
  • 14
    Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 2006; 88: 16170.
  • 15
    Eames NWA., Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 1999; 41: 22632.
  • 16
    Bartlett DJ, Palisano RJ. A multivariate model of determinants of motor change for children with cerebral palsy. Phys Ther 2000; 80: 598614.
  • 17
    International Classification of Functioning, Disability and Health. ICF Short Version. Geneva: World Health Organization, 2001.
  • 18
    Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth Scale of muscle spasticity. Phys Ther 1987; 67: 2067.
  • 19
    Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998; 18: 30411.
  • 20
    Novacheck TF, Stout JL, Tervo R. Reliability and validity of the Gillette Functional Assessment Questionnaire as an outcome measure in children with walking disabilities. J Pediatr Orthop 2000; 20: 7081.
  • 21
    Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the Gross Motor Function Measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther 2000; 80: 87385.
  • 22
    Ottenbacher KJ, Msall ME, Lyon NR, Duffy LC, Granber CV, Braun S. Interrater agreement and stability of the Functional Independence Measure for Children (WeeFIM): use in children with developmental disabilities. Arch Phys Med Rehabil 1997; 78: 130915.
  • 23
    Abidin RR. Parenting Stress Index, 3rd edn. Lutz: Psychological Assessment Resources, Inc., 1995.
  • 24
    Morgan GA, Busch-Rossnagel NA, Barrett KC, Harmon RJ. The Dimensions of Mastery Questionnaire: a manual about its development, psychometrics and use [Internet]. Fort Collins (CO): Colorado State University, School of Education, 2007 March 14 [cited 2009 March 5]. Available from: http://mycahs.colostate.edu/George.Morgan/docs/DMQmanual%20_03142007_.pdf (with permission).
  • 25
    Bottos M, Benedetti MG, Salucci P, Gasparroni V, Giannini S. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol 2003; 45: 75862.
  • 26
    Kay RM, Rethlefsen SA, Fern-Bunco A, Wren TAL, Skaggs DL. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am 2004; 86: 237784.
  • 27
    Ackman JD, Russman BS, Sienko Thomas S, et al. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 2005; 47: 62027.
  • 28
    Dickens WE, Smith MF. Validation of a visual gait assessment scale for children with hemiplegic cerebral palsy. Gait Posture 2006; 23: 7882.